Several months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed another drug in the class – Teva’s Ajovy – in draft guidance.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback